Results 131 to 140 of about 49,092 (212)

Safety of Nonsteroidal Anti‐Inflammatory Drug Use in Traumatic Brain Injury

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 10, October 2026.
ABSTRACT Background Use of nonsteroidal anti‐inflammatory drugs (NSAIDs) after a traumatic brain injury (TBI) is controversial due to potential worsening of an intracranial hemorrhage (ICH). This study evaluated if NSAID use within 14 days of TBI was associated with a clinically significant progression of intracranial bleed (PIB).
Jennifer Beavers, Mary Katherine Cella Shultz, Leanne Atchison, Cara Lwin, Dandan Liu, Silky Chotai, Andrew J. Medvecz, Robel Beyene, Michael C. Smith, Bradley M. Dennis, Susan Hamblin   +10 more
wiley   +1 more source

A Team‐Based Patient Engagement Approach to Selexipag Initiation and Maintenance in Pulmonary Arterial Hypertension (TEAM PAH): Real‐World Dosing Patterns and Persistence Among Patients With and Without a History of Methamphetamine Use

Pulmonary Circulation, Volume 16, Issue 4, October 2026.
ABSTRACT Selexipag is an oral prostacyclin receptor agonist approved for pulmonary arterial hypertension (PAH). This single‐center, retrospective study described oral selexipag dosing patterns and persistence, overall and stratified by history of methamphetamine (meth) use, at an expert center in California, USA, using a multidisciplinary, nurse ...
Samuel B. Brusca, Amanda Schnell Heringer, Mark Joshua Lacsamana, Anya Thakur, Jonathan Thomas, Christina Benninger, Gurinderpal Doad, Paul Strachan, Sarah Walden, Ambika Satija, Gayatri Marathe, Henrietta Blinder, Marjolaine Gauthier‐Loiselle, Teresa De Marco   +13 more
wiley   +1 more source

Identifying a Cardio‐Hepatic Phenotype by Integrating the Albumin‐Bilirubin Score Into Risk Assessment in Pulmonary Arterial Hypertension

Pulmonary Circulation, Volume 16, Issue 4, October 2026.
ABSTRACT Risk stratification is essential in pulmonary arterial hypertension (PAH), yet the prognostic utility of the albumin‐bilirubin (ALBI) score as a marker of hepatic dysfunction remains underexplored. In this single‐center study, we evaluated the clinical, neurohumoral, echocardiographic and hemodynamic correlates and prognostic value of the ALBI
Hacer Ceren Tokgoz, Barkin Kultursay, Seda Tanyeri, Dicle Sırma, Cagdas Bulus, Tezel Kovanci, Mustafa Kara, Seyma Zeynep Atici, Seyma Nur Cicek, Caglar Emre Cagliyan, Azmican Kaya, Faruk Akalin, Dogan Sen, Leyla Aliyeva, Nihal Ozdemir, Cihangir Kaymaz   +15 more
wiley   +1 more source

Hyponatremia and bone: an emerging relationship

, 2012
Hyponatremia is the most common electrolyte disorder and is mainly known for its neurological complications. New studies suggest previously unrecognized complications of hyponatremia, including falls, osteoporosis and fractures.
Liamis, G., Hoorn, E. J., Zillikens, M. C., Zietse, R.   +3 more
core  

Diuretics for Management of Bronchopulmonary Dysplasia Associated Pulmonary Hypertension in Preterm Infants—A Systematic Review

Pulmonary Circulation, Volume 16, Issue 4, October 2026.
ABSTRACT Bronchopulmonary dysplasia associated pulmonary hypertension (BPD‐PH) in preterm infants results from impaired pulmonary vascular development and contributes significantly to morbidity and mortality. Diuretics are commonly used to reduce pulmonary vascular congestion and improve oxygenation, but their efficacy and safety remain unclear.
Uthaya Kumaran Kanagaraj, Ayman Saker, Carlos Cuello‐Garcia, Michael Castaldo, Sandesh Shivananda   +4 more
wiley   +1 more source

Effect of experimental hypoosmolar hyponatremia on the blood brain barrier and brain edema formation

Scientific Reports
The most frequent cause of hyponatremia is water retention due to the increase in blood levels of antidiuretic hormone (vasopressin, AVP). Hyponatremia is associated with neurological deficits, which are mainly linked to brain edema.
Marta Aleksandrowicz, Przemysław Wencel, Mateusz Kciuk, Mariusz Popek, Łukasz Przykaza   +4 more
doaj   +1 more source

Interhospital Transfer Patients With Necrotizing Soft Tissue Infections: An Evaluation of the Role for Pretransport Operation

World Journal of Surgery, Volume 50, Issue 10, Page 2861-2865, October 2026.
Among transferred NSTI patients, mortality did not differ between PRE and the remainder of the cohort. PRE patients had longer hospital stays and higher healthcare charges, possibly due to worse physiology or more complex wounds. ABSTRACT Background Early debridement is the cornerstone of treatment for necrotizing soft tissue infections (NSTI), but ...
Hans V. Strobl, Diane N. Haddad, Renee Bicaba, Renee I. Tristano, Phillip M. Dowzicky, Abid D. Khan, Timothy P. Plackett, Justin S. Hatchimonji   +7 more
wiley   +1 more source

Low Serum Alkaline Phosphatase Levels in Paediatric sepsis Correlate With Acute Kidney Injury: A Multicenter Retrospective Study

Acta Paediatrica, Volume 115, Issue 10, Page 2315-2322, October 2026.
ABSTRACT Aims To investigate the association between serum ALP levels and the development of AKI in paediatric patients with sepsis. Methods Retrospective screening of a computerized database of 4 Israeli regional hospitals for children (0–18 years) hospitalized between 1.01.2000–1.06.2024 with ICD‐9 sepsis‐related diagnoses (study group) and age‐ and ...
Evgenia Gurevich, Ido Levi, Yehonatan Marziano, Michael Kalinin, Natalya Bilenko, Daniel Landau   +5 more
wiley   +1 more source

Serum Copeptin Rises After Tolvaptan for Hyponatraemia, but Does Not Predict Risk of Rapid Sodium Rise: Pre‐Specified Secondary Analysis of the TVFR Trial

Clinical Endocrinology, Volume 105, Issue 4, Page 514-518, October 2026.
ABSTRACT Objective Hyponatraemia is a common electrolyte disorder often driven by excess arginine vasopressin (AVP). Copeptin is a stable surrogate marker co‐secreted with AVP. It is unclear whether treatment of hyponatraemia with tolvaptan, an AVP‐V2 receptor antagonist, impacts copeptin.
Annabelle M. Warren, Kay Weng Choy, Rudolf Hoermann, Nicholas Russell, Mathis Grossmann   +4 more
wiley   +1 more source

Tenapanor Beyond Phosphate: Gut Sodium Transport, Stool Transit Time, and Volume Balance in Dialysis Patients

Hemodialysis International, Volume 30, Issue 4, Page 689-697, October 2026.
ABSTRACT Introduction Tenapanor, a minimally absorbed intestinal NHE3 inhibitor approved for hyperphosphatemia in dialysis, lowers phosphate and reduces intestinal sodium absorption. Its sodium–water signal may have implications beyond phosphate but remains poorly separated from diarrhea‐mediated losses and dialysis prescription artifacts. Methods This
Lucas Maciel de Almeida Corrêa, Luiggi Kevin Virgino Brandão, Clara Belo Gamon Santiago, Alexandre de Assis Barbosa, Gabriel Rian Mazur, Gabriel Costa de Santana, Yan Roberth Delmiro Silva, Letícia Esteves Dante, Ivan Felipe Dutra Júnior   +8 more
wiley   +1 more source